The "second messenger" archetype cAMP is one of the most important cellular signalling molecules with central functions including the regulation of insulin and glucagon secretion from the pancreatic β-and α-cells, respectively. cAMP is generally considered as an amplifier of insulin secretion triggered by Ca 2+ elevation in the β-cells. Both messengers are also positive modulators of glucagon release from α-cells, but in this case cAMP may be the important regulator and Ca
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have a more permissive role. The actions of cAMP are mediated by protein kinase A (PKA) and the guanine nucleotide exchange factor Epac. The present review focuses on how cAMP is regulated by nutrients, hormones and neural factors in β-and α-cells via adenylyl cyclase-catalysed generation and phosphodiesterase-mediated degradation. We will also discuss how PKA and Epac affect ion fluxes and the secretory machinery to transduce the stimulatory effects on insulin and glucagon secretion. Finally, we will briefly describe disturbances of the cAMP system associated with diabetes and how cAMP signalling can be targeted to normalize hypo-and hypersecretion of insulin and glucagon, respectively, in diabetic patients.
K E Y W O R D S
β-cell, glucagon, incretins, insulin secretion, islets, type 2 diabetes
| INTRODUCTION
The islets of Langerhans in the pancreas are essential for maintenance of normal glycaemia. The islet β-cells release blood glucoselowering insulin in response to postprandial hyperglycaemia, and when the glucose concentration falls below the normal level between meals or during starvation, the α-cells secrete the major blood glucose-elevating hormone glucagon. Glucagon together with another blood glucose-elevating hormone, adrenaline, acts on their respective liver receptors to generate cAMP, which activates a liver phosphorylase to convert glycogen to glucose. 1 The term "second messenger"
was accordingly coined for cAMP and it soon became clear that changes in the cytoplasmic cAMP concentration mediate the actions of many hormones. 1 A role of cAMP in insulin release was first indicated by the observation that secretion is promoted by glucagon. 2 It was soon verified that this effect is mimicked by other cAMPelevating agents, and that adrenaline inhibition of insulin secretion is associated with lowering of cAMP. 3, 4 It was even proposed that glucose stimulation of insulin secretion is mediated by cAMP formation triggered by binding of the sugar to receptors on the β-cell surface. 5 This concept was later refuted, and it was shown that cAMP does not initiate insulin release but is a potent amplifier of secretion that is already stimulated by glucose. 6 It was early clarified that presence of extracellular Ca 2+ is a prerequisite for glucose-stimulated insulin release. 7 Subsequent studies resulted in a consensus hypothesis in which glucose metabolism regulates insulin release via formation of ATP, closure of ATP-sensitive K + (K ATP ) channels, β-cell depolarization, opening of voltage-dependent Ca 2+ channels, influx of the ion and elevation of the cytoplasmic Ca 2+ concentration ([Ca   2+ ] i ), which is the primary trigger for exocytosis of insulin granules. 8 In addition to the Ca 2+ -dependent triggering pathway, glucose activates a metabolic amplification pathway, which augments insulin secretion by enhancing the efficiency of the triggering signal without influencing [Ca 2+ ] i. 8 Several metabolic factors are probably involved in mediating this effect.
" cAMP is essential not only for neurohormonal amplification of insulin release but also for glucose-stimulated secretion.
"
As cAMP is generated in response to glucose (see below), the messenger has come into fashion again and must be considered not only when discussing neurohormonal amplification of insulin release but also when analysing glucose-stimulated secretion. There is even a recent revival of the external glucoreceptor concept with the discovery that artificial sweeteners acting on sweet taste receptors may contribute to the glucose action on β-cells with unclear signalling (possibly cAMP and Ca 2+ ) mediating ATP elevation 9 but the contribution of such receptors to the glucose effect is probably modest compared to the consensus triggering and amplifying pathways.
The importance of cAMP in glucagon secretion became obvious with the observation that adrenaline promotes glucagon release 10 by β-adrenergic activation of cAMP formation in the α-cells that contrasts to the α 2 -adrenergic cAMP reduction in the β-cells. 11 Glucagon has also a positive feedback effect on its own release by elevating cAMP in the α-cells. 12, 13 The synergistic effects of glucagon and adrenaline on α-cell cAMP and glucagon release are paralleled by the synergism between the 2 hormones on liver cAMP and glycogenoly- . [16] [17] [18] This review focuses on metabolic and receptor-mediated changes in cAMP as well as the molecular mechanisms by which cAMP partakes in the regulation of blood glucose by modulating the release of insulin and glucagon but will not cover effects of cAMP on islet cell proliferation and survival or transcriptional regulation of secretion.
| COMPONENTS OF THE cAMP SIGNALLING SYSTEM
cAMP is generated from ATP by adenylyl cyclases (ACs), an enzyme family with 10 members many of which are expressed in islet cells 19, 20 (see also reviews 21, 22 ). All but 1 isoform is regulated by G- isoforms in α-cell function is yet poorly defined.
The concentration of cAMP is also regulated at the level of degradation by cyclic nucleotide phosphodiesterases (PDEs), which catalyse the hydrolysis of cAMP to 5 0 -AMP. The role of PDEs in islets has previously been reviewed. 21, 22 There are more than 50 PDE isoforms divided into 11 families. PDE3B seems to be quantitatively dominating in islets and functionally important for insulin secretion. 29, 30 It is activated by glucose, insulin, IGF-1 and cAMP via alterations of PKAand PKB-mediated phosphorylation. 30, 31 PDE1, PDE4 and PDE8 family members are also present in islets and contribute to the shaping of cAMP signals 32 and regulation of insulin secretion. 21, 22, 31, 33 PDE3B has been proposed to participate in insulin suppression of glucagon secretion 34 but detailed information about α-cell PDEs in glucagon secretion is still missing. Epac is a guanine nucleotide exchange factor for Rap GTPases that has lower affinity for cAMP than PKA. There are 2 isoforms, Epac1 and Epac2, with 3 alternatively spliced forms of the latter.
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Epac2 is the predominantly expressed isoform in islets and deletion of the protein reduces the stimulatory effect of cAMP on insulin secretion with modest effects on glucose-induced release 36 unless the animals are exposed to metabolic stress. 37 Knockout of Epac1 leads to disrupted islet cytoarchitecture with impaired insulin secretion and glucose tolerance. 38 The roles of PKA and Epac in the regulation of insulin and glucagon secretion are described in more detail below. As an alternative to FRET readout, our laboratory developed a ratiometric reporter undergoing cAMP-induced changes in localization (translocation). 43 A fluorescent-protein-tagged, truncated version of the PKA regulatory subunit is anchored to the plasma membrane via a posttranslational modification. The PKA catalytic subunit, tagged with a spectrally different fluorescent protein, will then translocate to and from the plasma membrane in response to changes of the cAMP concentration in the subplasma membrane space. 43 The main limitations with this sensor are that it requires a balanced expression of the 2 moieties and that it cannot easily be applied for cAMP measurements in other subcellular compartments. However, the submembrane cAMP dynamics is relevant because it is where receptors, ACs and ion channels are located and secretory granules undergo exocytosis. The translocation sensor has successfully been employed in insulinoma cells, [43] [44] [45] [46] isolated β-cells 44 as well as in α-and β-cells within intact pancreatic islets. for a potentiating effect of glucagon. However, glucagon release is significant even when maximally inhibited by 5 to 7 mM glucose and tends to increase at higher glucose concentrations, 47 indicating that islet glucagon may help to reduce blood glucose by stimulating insulin release under conditions when insulin and glucagon should have opposite actions on glucose mobilization from the liver. In diabetes, the glucose-mobilizing effect apparently dominates because glucagon hypersecretion plays a key role in the clinical manifestations of the disease. 48 The importance of islet glucagon may also depend on species since hormone from the peripheral α-cells in rodent islets does not necessarily reach the bulk of centrally located β-cells whereas the more even distribution of the different cell types in human islets should favour paracrine interactions. However, one should be aware that islet α-cells are not the only source of glucagon, which is also secreted from the stomach and intestine. 48 The observation that the plasma insulin response to an oral glucose load is much more pronounced than after intravenous glucose administration was originally attributed to additional stimulation by gastrointestinal or liver factors forming the basis for the incretin concept. 49 The most important incretin hormones are glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), 49 which are secreted from gastrointestinal L-and K-cells, respectively, in response to nutrients. GLP-1 in particular has several beneficial properties for treatment of type 2 diabetes as it not only promotes insulin release but also inhibits that of glucagon, 50 whereas GIP stimulates secretion of both hormones and may contribute to glucagon-dependent hyperglycaemia in diabetes. 51 Like glucagon, 46 and galanin on its receptor(s). 56 However, ghrelin, which was previously thought to act on Gα i -coupled β-cell receptors was recently found to activate Gα i -signalling indirectly by stimulating somatostatin secretion. 57 Like the case for cAMP-elevating agonists, also those with lowering effect act by additional mechanisms. Adrenaline, noradrenaline, somatostatin and galanin are thus known to activate K + channels to hyperpolarise β-cells and inhibit L-type Ca 2+ channels, 55, 56 and to inhibit exocytosis at a distal site mediated by acylation of essential exocytosis proteins 56 or by activation of the Ca 2+ -dependent serine/threonine protein phosphatase calcineurin. 58 
| MEASUREMENTS OF cAMP

| GLUCOSE-INDUCED cAMP SIGNALLING IN β-CELLS
cAMP signalling is not only triggered by receptor agonists and it was early found that also glucose increases the islet cAMP content. 6, 39, 40, 59 The effect was suggested to depend on the -sensitive PDE1.
Our recordings of the subplasma membrane cAMP dynamics have shown that glucose promotes cAMP elevation with pronounced oscillations (Figure 1 ). Two mechanisms are involved:
one dependent on Ca 2+ and another reflecting stimulated cell metabolism. 44 
"
Like the triggering and amplifying pathways for insulin secretion, cAMP is regulated both by Ca 2+ and glucose metabolism.
The 2 components can be showed with an experimental protocol resembling that used to define the triggering and amplifying pathways of glucose-stimulated insulin secretion. 8 Consistent with a stimulatory effect of Ca 2+ , β-cells exposed to a substimulatory glucose concentration react with cAMP elevation after depolarization with high K + in the presence of the K ATP channel opener diazoxide ( Figure 1 ). When the glucose concentration is increased, there is further elevation of cAMP. 44 A similar metabolic amplification of cAMP production was found with the mitochondrial substrate α-ketoisocaproic acid. 27 have highlighted AC9 and AC5, respectively, as important mediators of glucose-induced cAMP formation. These isoforms are subject to multiple regulatory inputs but the stimulatory effect of glucose may simply reflect increased availability of ATP, the substrate for all ACs. 44 However, since the ATP concentration is potentially saturating even under low glucose conditions, glucose may instead act via lowering of AMP to relieve its inhibitory effect on AC activity. 63 As mentioned above, the soluble AC (sAC), has lower affinity for ATP and has been suggested to play a role in glucose sensing in INS-1 cells 64 and islets. 28 Evaluation of the functional importance of sAC has been complicated by toxic side effects of the commonly used inhibitor KH7. 13 Interestingly, islets from sAC-deficient mice exhibit reduced glucose-stimulated insulin secretion but it is not known if this reduction reflects impaired cAMP formation. 68 The Epac proteins are also spatially regulated and elevations of cAMP induces translocation of Epac2 from the β-cell cytoplasm to the plasma membrane 69 ( Figure 2 ). The binding to the cAMP signals generated by the transmembrane ACs can be expected to be most pronounced near the plasma membrane. The submembrane compartment is particularly relevant for the regulation of ion channels and for the docking, priming and exocytosis of insulin granules. However, cAMP formation continues after the receptorligand-AC complex has been internalized in endosomes. 75 Mathematical modelling has indicated that there is no steep cAMP concentration gradient between the plasma membrane and cytosol after GLP-1 receptor activation, 74 and cAMP oscillations have been observed both with plasma membrane-localized reporters 13, 26, 43, 44 and nontargeted cytosolic sensors. 61, 73 Even if the absolute concentrations may differ, the kinetic pattern seems to be similar in the submembrane and deeper cytosol. of exocytosis. 81 It is now well established that both effector proteins promote insulin secretion by influencing multiple steps in the stimulus-secretion coupling process.
| Role of cAMP in glucose-stimulated insulin secretion
Before discussing the mechanisms underlying cAMP amplification of glucose-stimulated insulin secretion in more detail, it should be pointed out that cAMP is significant also for the ability of glucose to initiate insulin secretion. When β-cells are exposed to a step increase of the glucose concentration there is an initial, distinct increase of insulin release lasting for a few minutes (first phase) followed by a decline and increase to a new steady-state (second phase). This pattern has been explained by the release of different granule pools, where the first phase corresponds to exocytosis of readily releasable granules and can be triggered by [Ca 2+ ] i elevation alone, whereas the second phase reflects energy-requiring recruitment and priming of new granules for exocytosis. 82 However, such distinction has been questioned, because both phases of secretion seem to involve the triggering and amplifying pathways, 8 and when studied with sufficient temporal resolution, it is evident that the second phase secretion consists of pronounced pulses with a 2-to 5-minute periodicity, as if the first phase were recurring repeatedly. 8, 83 Single-cell optical recordings in MIN6 and mouse β-cells have showed that the initial secretory response is markedly impaired after inhibition of ACs or PKA, 45, 84 indicating that basal, constitutive PKA activity has a permissive effect (Figure 3 ). The reduced initial response to glucose after PKA inactivation has been explained by an intricate effect on the K ATP channels, resulting in accelerated depolarization with subsequent dissociation of the triggering [Ca 2+ ] i elevation and the amplifying cAMP signals. 45 Suppression of glucose-induced cAMP formation with AC inhibitors impairs also the second phase of insulin secretion. 22, 44, 45 This finding is consistent with the observations that PKA is activated in glucose-stimulated β-cells 25 and that ATP regulates insulin exocytosis in a PKA-dependent manner. 85 However, other observations indicate that PKA inhibitors have only modest effects on established glucose-induced insulin release 45 ( Figure 3C ), indicating involvement of Epac. Although cAMP evidently is important for the ability of glucose to stimulate insulin secretion, it only seems to account for a fraction of the metabolic amplification by glucose. 86 
| cAMP amplification of first and second phase insulin secretion
cAMP-elevating agents do not affect insulin secretion unless β-cells are exposed to glucose concentrations at or above the threshold for stimulation of insulin release. Animals deficient in Epac proteins, [36] [37] [38] or with genetic activation of PKA, 37 and the use of cAMP analogues that selectively activate PKA or Epac 37,86-88 have helped to define the roles of the 2 effectors in insulin secretion from mouse and human islets. Dynamic recordings of insulin secretion from mouse islets exposed to effector-specific activating nucleotides indicate that cAMP amplification of insulin release is mainly mediated by Epac during the first phase, whereas both PKA and Epac contribute to second phase secretion. 86 This conclusion is consistent with results from capacitance measurements of exocystosis. 80, 89 The combination of PKA and Epac activators is more efficient than either activator alone. 86 However, the effect of Epac activation is prevented by PKA inhibition in human islets, 87 but this is not the case in the mouse.
36,86,88
| cAMP effects on metabolism
It has been observed that elevations of cAMP by GLP-1 and forskolin stimulate ATP production in mouse islets. 90 In contrast, no effects on ATP production or oxygen consumption were observed in another study using conventional biochemical approaches. 91 Whether cAMP influences metabolism thus remains controversial, and it is unclear how quantitatively important such an effect would be in relation to established actions on the more distal steps of the stimulus-secretion-coupling process.
| cAMP effects on electrical activity and Ca
2+ signalling
It has long been known that cAMP promotes electrical activity with Ca 2+ signalling in islets and β-cells. 92 These effects are largely explained by the action of PKA on K ATP 93 and voltage-dependent Ca 2+ channels. 94 Closure of K ATP channels may also be facilitated by Epac2, 95 which binds to the SUR1 subunit of the channel. 81 The underlying mechanism is unclear but has been suggested to involve activation of phospholipase C-ε 96 with concomitant lowering of PIP 2 , which in turn shifts the ATP-sensitivity of the channel. cAMP has been found to contribute to glucose-and GLP-1-induced β-cell depolarization also via PKA-independent activation of the non-selective cation channel TRPM2, 97 and via activation of niflumic acid-sensitive Cl − channels, supposedly involved in β-cell sensing of gradual changes of the glucose concentration. 98 The effects of cAMP on β-cell Ca 2+ signalling is not restricted to regulation of membrane potential and voltage-dependent Ca 2+ influx, but also involve mobilization of the ion from intracellular stores. The latter effect is essentially due to PKA-induced sensitization of IP 3 receptors. 99 Epac has been proposed to promote Ca 2 + -induced Ca 2+ release via ryanodine receptors, 100 but later studies from the same laboratory instead favour IP 3 -gated Ca 2+ release secondary to the Epac/Rap1-mediated activation of phospholipase C-ε. 96 
| cAMP effects on secretory granules and exocytosis
Although the cAMP effects on electrical activity and [Ca 2+ ] i signalling contribute to the amplification of insulin secretion, the quantitatively most important effects are exerted on secretory granule trafficking and exocytosis. 93 Both PKA and Epac promote secretory granule mobility, which leads to accelerated replenishment of readily releasable granules at the plasma membrane. 36, 80, 89 Before the vesicles are ready to fuse with the plasma membrane they undergo
priming by yet incompletely understood mechanisms. For example, the Rab3-binding protein Rim2α, which interacts with Epac2, has been implicated in granule priming. 101 Granular acidification by the electrogenic vacuolar type H + -ATPase is one of the critical steps and simultaneous uptake of Cl − and glutamate is believed to increase the proton gradient by neutralizing the charge. 102 Indeed, PKA was recently found to stimulate vesicular uptake of glutamate. 103 Previous studies have shown that SUR1 knockout mice lack the PKA-independent component of cAMP-amplified exocytosis, and this was ascribed to the loss of interaction between Epac2 and the SUR1 protein supposedly involved in granular Cl − uptake. 89 More recent studies indicate that the cAMP-regulated CFTR protein, in addition to regulating β-cell electrical activity, 104 is crucial for cAMP-amplified insulin secretion by stimulating vesicle priming via the Cl − channel anoctamin 1.
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In addition to increasing the number of granules available for release, cAMP also influences the exocytosis process. The stimulation is partly due to sensitization of the exocytosis machinery to Ca 2+ , an effect that mainly seems mediated by PKA. 106 Several proteins in the exocytosis machinery are substrates for PKA and/or interact with Epac, which may influence SNARE complex formation.
SNAP-25 107 and Snapin 108 are particularly interesting proteins that interact with both cAMP effectors, as well as additional exocytosis proteins. 
| Regulation of α-cell cAMP by receptor agonists
As mentioned above, adrenaline promotes glucagon release 10 by β-adrenergic activation of cAMP formation in the α-cells 11 and glucagon has a feed-forward effect on its own release by elevating cAMP. 12, 13 Adenosine is another stimulator of glucagon secretion whose effect is mediated by Gα s -coupled A 2A receptors. 113 The incretin hormone GIP also amplifies glucagon release by G-protein-coupled elevation of α-cell cAMP. 114 However, the mechanism by which the other incretin, GLP-1, inhibits glucagon release is not settled. As capacitance measurements on single rat α-cells indicated that both GIP and GLP-1 amplify exocytosis of glucagon it was proposed that GLP-1 may inhibit glucagon secretion indirectly by stimulating somatostatin release. 115 A later study from the same group instead showed that GLP-1 inhibition of glucagon release occurs independently of any increase in somatostatin or insulin release. 112 It was therefore proposed that GLP-1 inhibits glucagon release by inducing a small cAMP elevation in the α-cells due to low GLP-1 receptor expression, whereas adrenaline becomes stimulatory by inducing a large elevation. Indeed, inhibition and stimulation of glucagon secretion could be mimicked by low and high concentrations of AC-activating forskolin. 112 However, direct recordings of cAMP indicated that individual α-cells located within islets only rarely respond to GLP-1. 13 The question therefore arises if GLP-1 inhibits glucagon release independent of changes in cAMP by interacting with yet unidentified α-cell receptors.
Whereas adrenaline inhibits insulin and stimulates glucagon release, somatostatin potently inhibits secretion of both hormones with stronger effect on the α-cells, 116 which preferentially express somatostatin type 2 receptors in both rodents 54 and humans. 55 Like in β-cells the effect of somatostatin on α-cells is mediated by Gα icoupled inhibition of AC and by depriming of glucagon secretory granules after activation of calcineurin 117 as well as by activation of G-protein-gated K + channels. 55 Glucagon secretion from human α-cells is also inhibited by serotonin, which activates Gα i -coupled 5-HT 1F receptors to reduce cAMP. 118 A different mode of cAMP reduction has been proposed for the insulin receptor, mediating increased cAMP degradation via activation of PDE 3B. Glucose regulates cAMP by a direct effect on the α-cell, which is more important for glucagon secretion than changes in Ca 2+ . 14 There is also a stimulatory component in the glucose effect on glucagon release from mouse and human islets that is evident as diminished inhibition of secretion with increasing hyperglycaemia, 47 and as glucose stimulation of secretion from purified rat and mouse α-cells. 121 Moreover, the cAMP-mediated feed-forward effect of glucagon on its release apparently contributes to the paradoxical hyperglucagonemia in diabetic hyperglycaemia. 12, 13 The other major defect of glucagon release in diabetes is the failure to respond to hypoglycaemia with increased secretion, offering little protection against lifethreatening hypoglycaemia in aggressive diabetes therapy. 122 This failure to respond to sudden hypoglycaemia may simply result from glucagon secretion being close to maximally stimulated already in diabetic hyperglycaemia.
The secretion of the incretin hormones is compromised in type 2 diabetes with significantly reduced postprandial GLP-1 and less affected GIP release. 123 The reduction of GLP-1 contributes to hyperglycaemia by decreased potentiation of insulin release and increased secretion of glucagon. As GLP-1 and GIP are rapidly degraded by dipeptidyl peptidase (DPP4), inhibitors of this enzyme have been successfully used in type 2 diabetes therapy. Another approach is GLP-1 analogues that are resistant to DPP4 degradation.
Such analogues offer the advantage of mimicking the amplifying and inhibiting effects of GLP-1 on insulin and glucagon secretion, respectively, 50 whereas DPP4-mediated reduction of GIP degradation would tend to promote the release of both insulin and glucagon. 51 
| Diabetes risk genes affecting cAMP
Since cAMP is a key amplifier of insulin secretion it is not unexpected that genome-wide association studies have revealed that human type 2 diabetes is associated with different mutations affecting cAMP signalling. One risk allele lowers the expression of AC5 in islets and reduces glucose-induced cAMP generation as well as insulin secretion with minor effects on incretin action. 27 Another mutation causes overexpression of the α 2A-adrenergic receptor resulting in inhibition of insulin release after Gα i -coupled reduction of cAMP formation and calcineurin activation. 124 A similar example is a polymorphism leading to increased expression of the Gα i -coupled melatonin receptor 1b with reduced cAMP formation and insulin secretion, 46 but persistent activation of this receptor has also been implicated in improved β-cell function and survival in type 2 diabetes-related molecular stress. ( Figure 5 ). The effects of hyperglycaemia may be aggravated by lowered PKA activity caused by increased expression of the PKAinhibiting peptide PKIβ. 127 These results contrast to findings from diabetic GK rats, in which insulin secretion is reduced despite increased islet expression of several ACs, including AC3 and AC8. 20, 24 It is possible that the altered cAMP metabolism in this model reflects compensation for other defects. Another diabetes model, the neonatal streptozotocin-treated rat, shows impairment of glucose-induced cAMP formation in β-cells with reduced insulin secretion, which is reversed by treatment with cAMP-elevating agents. 128 
"
Disturbances in cAMP signalling contribute to impaired islet cell function in type 2 diabetes.
The above examples indicate that genetic variations and metabolic conditions that compromise the cAMP signalling pathway in β-cells both contribute to type 2 diabetes. Apart from deteriorated cAMP amplification of insulin secretion, loss of β-cell mass is expected in the long run, because cAMP protects from apoptosis. 129 In any case, the cAMP system offers different potential targets for treatment and prevention of 2 diabetes, like specific inhibitors of overexpressed Gα i -coupled receptors 124 or activation of alternative pathways for cAMP generation. 
